![]() |
|
|||||||||||
|
![]() |
|
||||||||||
|
Bridging the Distance Between Pathogenesis and Disease CHORI Scientists Propose New Model for Protein Associated with Parkinson’s Disease
In a new study published in the September issue of Biochemistry – the official biochemical journal of the American Chemical Society – and highlighted as a “hot” article in their online press, CHORI scientists Vasanthy Narayanaswami, PhD, Shiori Tamamizu-Kato, PhD and their colleagues propose for the first time a model for the lipid membrane interaction of alpha-synuclein (alpha-syn), a soluble protein found primarily in neuronal tissues. Alpha-syn is most notable, however, for its potential role in the pathogenesis of Parkinson’s disease (PD). “The Lewy bodies found in PD are composed predominantly of aggregated alpha-syn and lipids,” explains Dr. Narayanaswami. “It’s one of the hallmark features of the disease.” Although it is generally well-accepted that the accumulation and aggregation of alpha-syn is a critical player in the development of PD, its structure and function have remained elusive to date. “Normally, proteins have a primary and a secondary structure,” explains CHORI scientist Vasanthy Narayanaswami, PhD. “Imagine the primary structure as a chain of beads, with each bead being an amino acid.” This strand of amino acid “beads” doesn’t remain linear, however, but folds into a secondary structure such as an alpha-helical or a beta-sheet structure. “How a protein folds is an intrinsic property of that protein,” continues Dr. Narayanaswami. “But alpha-syn has no secondary structure and doesn’t fold in solution, which is very rare.” The unstructured or linear state of alpha-syn has been known for some time. Alpha-syn, consists of an N terminal domain, a beta-amyloid binding domain, and a C terminal tail. What is not clear is how this unstructured form of the protein binds lipids, a critical step in ultimately identifying the process by which alpha-syn aggregates in the Lewy bodies associated with PD. “What happens to alpha-syn when you present it with a membrane surface is that the N-terminal part of the protein forms an alpha-helical structure upon binding to the membrane,” Dr. Narayanaswami says. “The C-terminal tail, which is rich in negatively charged amino acid residues, does not bind because the cell membrane, which also has a negative charge, repels the tail.”
“What our model shows is that calcium, when added to alpha-syn after the N-terminal has bound with a lipid, serves as a bridge between the C-terminal tail and the membrane lipid, so that the whole protein, not just the N-terminal domain, is attached to the lipid surface.” Even more interesting, is that when the C-terminal tail of alpha-syn binds with the lipids in the presence of calcium, it becomes a beta-sheet structure. “Formation of a beta sheet structure is not very desirable in these kind of situations,” explains Dr. Narayanaswami, “because it represents an irreversible structure – it can not ever go back to the way it was. In fact, it becomes a template, with more proteins adding on to it creating a domino effect.” As a result, the new calcium-triggered model of membrane interaction proposed by Dr. Narayanaswami, Dr. Tamamizu-Kato and their colleagues could describe the potential mechanisms responsible for the aggregation of alpha-syn in Lewy bodies. While their model provides a clue to the bridging mechanism in alpha-syn aggregation, it also represents a significant step toward bridging the gaps in our knowledge of the pathogenesis of PD. This work was funded by grants from the Parkinson’s Disease Foundation and the Alzheimer’s Association. |
||||||||||||
|
© 2005 Children's Hospital Oakland Research Institute |
||||||||||||